You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory B Cell ALL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

B-cell Acute Lymphoblastic Leukemia Trial in United States (Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Inotuzumab ozogamicin
  • +6 more
  • Nashville, Tennessee
  • +3 more
Aug 14, 2022

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

B-cell Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel)

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • Tisagenlecleucel
  • (no location specified)
Feb 3, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

Not yet recruiting
  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
  • (no location specified)
Sep 25, 2023

Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That

Not yet recruiting
  • Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
  • Inotuzumab Ozogamicin
  • (no location specified)
Nov 3, 2022

Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 19, 2023

CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)

Recruiting
  • CAR
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • U-CAR-T Cells (LstCAR019)
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • UCAR-T Cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022

B-cell Acute Lymphoblastic Leukemia Trial (single dose of CNCT19)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • single dose of CNCT19
  • (no location specified)
Dec 19, 2022

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Lymphoma (B-ALL) Trial (PIT565)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • B-cell Acute Lymphoblastic Lymphoma (B-ALL)
  • PIT565
  • (no location specified)
Jun 13, 2022

Acute Lymphoblastic Leukemia Trial in Suzhou (cladribine, cytarabine,venetoclax)

Recruiting
  • Acute Lymphoblastic Leukemia
  • cladribine, cytarabine,venetoclax
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 22, 2022

ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)

Not yet recruiting
  • ALL, Childhood B-Cell
  • +2 more
  • Tafasitamab
  • (no location specified)
Nov 25, 2022

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)

Active, not recruiting
  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
  • CD19-CD22 CAR-T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 2, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
  • Aurora, Colorado
    Children's Hospital Colorado
Nov 9, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Sanhe (GC007F)

Completed
  • B-cell Acute Lymphoblastic Leukemia
  • GC007F
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Apr 21, 2022

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

B-Cell Leukemia, B Cell Lymphoma Trial in Kunming (anti-CD19 UCAR-T injection)

Recruiting
  • B-Cell Leukemia
  • B Cell Lymphoma
  • anti-CD19 UCAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Apr 21, 2022

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston

Recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • +4 more
  • CD19.CAR-aNKT cells
  • +2 more
  • Houston, Texas
  • +1 more
Aug 19, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Nanchang (Human CD19 Targeted DASH CAR-T Cells Injection)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Human CD19 Targeted DASH CAR-T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022